# Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)

> **NCT01527435** · — · COMPLETED · sponsor: **The Retina Center of St. Louis County, PC** · enrollment: 200 (actual)

## Conditions studied

- Exudative Age-Related Macular Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01527435
- **Lead sponsor:** The Retina Center of St. Louis County, PC
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2016-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527435, "Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01527435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*